Gemina Laboratories Ltd. (GLABF)

Market Cap	1.69M -94.1%
Revenue (ttm)	7.76K
Net Income	-2.09M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,355
Average Volume	72,545
Open	0.0600
Previous Close	0.0691
Day's Range	0.0400 - 0.0649
52-Week Range	0.0375 - 0.9194
Beta	-0.04
RSI	33.41
Earnings Date	May 28, 2026

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLABF

Financial Performance

Financial numbers in CAD